Viral replicon particles protect IFNAR
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Disease Models, Animal
Female
Hemorrhagic Fever, Crimean
/ immunology
Immunogenicity, Vaccine
Male
Mice
Mice, Knockout
Receptor, Interferon alpha-beta
/ genetics
Replicon
/ immunology
Vaccination
Viral Vaccines
/ administration & dosage
Virion
/ immunology
Crimean-Congo hemorrhagic fever
IFNAR(−/−) mice
Vaccine
Viral replicon particle
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
09
04
2021
revised:
17
05
2021
accepted:
19
05
2021
pubmed:
28
5
2021
medline:
15
12
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
Crimean-Congo hemorrhagic fever virus (CCHFV) causes mild to severe and fatal disease in humans. Person-to-person transmission is common, necessitating the availability of rapidly deliverable therapeutic and prophylactic interventions to mitigate CCHFV spread. Previously, we showed complete protection using one dose of a viral replicon particle (VRP) vaccine administered 28 days before CCHFV challenge. In order to determine the utility of the VRP vaccine for rapid vaccination protocols, we assessed the efficacy of such vaccination administered at various intervals relative to challenge in IFNAR
Identifiants
pubmed: 34044061
pii: S0166-3542(21)00080-2
doi: 10.1016/j.antiviral.2021.105090
pmc: PMC9250103
mid: NIHMS1709752
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Ifnar1 protein, mouse
0
Viral Vaccines
0
Receptor, Interferon alpha-beta
156986-95-7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
105090Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI151006
Pays : United States
Informations de copyright
Published by Elsevier B.V.
Références
Viruses. 2019 Jun 28;11(7):
pubmed: 31261754
Antiviral Res. 2019 Oct;170:104573
pubmed: 31377243
J Med Virol. 2006 Feb;78(2):216-22
pubmed: 16372299
Int J Infect Dis. 2009 May;13(3):380-6
pubmed: 18986819
BMC Infect Dis. 2014 Jul 28;14:416
pubmed: 25066751
Int J Infect Dis. 2016 Apr;45:109-11
pubmed: 26972040
Emerg Infect Dis. 2007 Nov;13(11):1769-72
pubmed: 18217568
J Infect Dis. 2018 May 25;217(12):1957-1966
pubmed: 29800368
PLoS One. 2015 Feb 18;10(2):e0116816
pubmed: 25693189
PLoS One. 2015 Feb 26;10(2):e0118345
pubmed: 25719445
Emerg Microbes Infect. 2019;8(1):575-578
pubmed: 30947619
PLoS Pathog. 2019 Dec 2;15(12):e1008183
pubmed: 31790513
Antiviral Res. 2013 Oct;100(1):159-89
pubmed: 23906741
PLoS One. 2015 Mar 18;10(3):e0118434
pubmed: 25785602
PLoS Pathog. 2015 May 01;11(5):e1004879
pubmed: 25933376